State Street Corp Has $3.72 Million Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)

State Street Corp lowered its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 0.7% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 690,826 shares of the company’s stock after selling 4,597 shares during the quarter. State Street Corp owned about 1.22% of Design Therapeutics worth $3,717,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Frazier Life Sciences Management L.P. bought a new position in Design Therapeutics during the second quarter worth about $4,004,000. FMR LLC grew its position in shares of Design Therapeutics by 922.8% during the 3rd quarter. FMR LLC now owns 828,665 shares of the company’s stock worth $4,458,000 after purchasing an additional 747,649 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Design Therapeutics by 61.6% during the third quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company’s stock worth $8,612,000 after purchasing an additional 609,939 shares during the period. Almitas Capital LLC raised its position in shares of Design Therapeutics by 22.1% in the second quarter. Almitas Capital LLC now owns 1,253,248 shares of the company’s stock valued at $4,198,000 after buying an additional 227,180 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Design Therapeutics by 44.5% in the second quarter. Acadian Asset Management LLC now owns 583,160 shares of the company’s stock valued at $1,952,000 after buying an additional 179,614 shares during the period. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Price Performance

Shares of NASDAQ:DSGN opened at $6.17 on Tuesday. The company has a market capitalization of $349.35 million, a P/E ratio of -7.26 and a beta of 1.86. The business’s 50 day simple moving average is $5.98 and its 200 day simple moving average is $5.08. Design Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $7.77.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.